Corvus Pharmaceuticals Announces Publication of Preclinical Results Highlighting Antitumor Activity of CPI-444 in Multiple Tumor Models both as Monotherapy and in Combination Studies

Author's Avatar
Oct 04, 2018
Article's Main Image

As Combination, CPI-444 Showed Elimination of Tumors in 90% of Treated Mice and Restoration of Immune Response in Mice with Tumors Resistant to Therapy with anti-PD-1 and anti-CTLA-4